Abstract:CBF beta was recently found to be a key regulator of the ability of human immunodeficiency virus type 1 (HIV-1) Vif to overcome host antiviral APOBEC3 proteins. However, the detailed molecular requirements for the Vif-CBF beta interaction are still not clear. Here, we mapped the minimum Vif domain required for CBF beta binding. In terms of CBF beta binding, the Vif N terminus was very sensitive to deletions. We determined that the Vif fragment from residues 5 to 126 was sufficient to form a stable complex with CBF beta in vitro. We also observed that ionic interactions were not the main contributor to the interaction between Vif and CBF beta. Instead, hydrophobic interactions were important for maintaining the Vif-CBF beta complex, since it could be disrupted by nonionic detergent. Site-directed mutagenesis of conserved hydrophobic amino acids revealed novel residues in Vif that were important for CBF beta binding and APOBEC3 inactivation. At least part of the well-characterized HCCH domain (residues 108 to 139) was required to form a stable Vif-CBF beta complex. Thus, the HCCH motif may have a dual role in binding both Cul5 and CBF beta. Considering the importance of Vif in HIV-1 infection, this unique Vif-CBF beta interaction represents an attractive pharmacological intervention target against HIV-1. IMPORTANCE Vif-induced APOBEC3 protein degradation was the first host antiviral mechanism against HIV-1/simian immunodeficiency virus to be revealed, yet details regarding which proteins are degraded are not fully demonstrated. Recently, host cellular factor CBF beta was found to be essential for Vif to function and promote viral infectivity. In this study, we present more critical information on the Vif-CBF beta interaction by revealing that hydrophobicity contributes the most to the Vif-CBF beta interaction and locating several novel hydrophobic sites (tryptophans and phenylalanines) that are conserved among Vif proteins from different lentiviruses and essential for Vif binding to CBF beta. Mutations on these sites result in a reduced/abolished Vif-CBF beta interaction, leading to the attenuated potency of Vif on both inducing the degradation of antiviral factors like APOBEC3G and promoting HIV-1 infectivity. Therefore, information from this study will help people to further understand how Vif acts against host antiviral mechanism, which is important for novel anti-HIV-1 drug development.

Characterization Of Conserved Motifs In Hiv-1 Vif Required For Apobec3g And Apobec3f Interaction

A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Distinct Determinants In Hiv-1 Vif And Human Apobec3 Proteins Are Required For The Suppression Of Diverse Host Anti-Viral Proteins

Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.

USP49 Potently Stabilizes APOBEC3G Protein by Removing Ubiquitin and Inhibits HIV-1 Replication

Conserved and Non-Conserved Features of HIV-1 and SIVagm Vif Mediated Suppression of APOBEC3 Cytidine Deaminases.

Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F

Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.

Regulation of Apobec3f and Human Immunodeficiency Virus Type 1 Vif by Vif-Cul5-Elonb/C E3 Ubiquitin Ligase

HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain

Structural Basis of Antagonism of Human APOBEC3F by HIV-1 Vif

Suppression of APOBEC3-mediated restriction of HIV-1 by Vif

Identification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppression.

A Single Amino Acid Difference in Human APOBEC3H Variants Determines HIV-1 Vif Sensitivity

The structural basis for HIV-1 Vif antagonism of human APOBEC3G

Influence Of Primate Lentiviral Vif And Proteasome Inhibitors On Human Immunodeficiency Virus Type 1 Virion Packaging Of Apobec3g

Identification of an Hiv-1 Replication Inhibitor Which Rescues Host Restriction Factor Apobec3g in Vif-Apobec3g Complex

Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H

HIV-1 Vif N-terminal Motif is required for recruitment of Cul5 to Suppress APOBEC3

A Naturally Occurring Vif Mutant (I107T) Attenuates Anti-Apobec3g Activity and HIV-1 Replication.

Vif Hijacks CBF-β to Degrade APOBEC3G and Promote HIV-1 Infection